Targeted therapies are currently the focus of much anti-cancer drug development. They are a cornerstone of precision medicine, using information about a person’s genes and proteins to prevent, diagnose and treat disease. While these therapies show great promise, they are also very complex. These immuno-oncology and cytostatic treatments often require different assumptions and factors to be tested compared to traditional, early safety-based trials for cytotoxic agents. Clinical trial design is a critical factor that can make or break success. Careful foresight in initial stages can impact data quality and trial duration.
This webinar will address leading therapies in novel oncology trials. It will provide an in-depth perspective on what drug developers can do to find the right patients. It will offer insights into just how important biomarkers and companion diagnostics may be in targeted therapy clinical trials.
Attendees will gain important insights from experts developing some of the most innovative oncology clinical trials today.
Deb Kientop, MBA, Vice President, Oncology Development, Synteract
Kientop brings over 25 years of experience in oncology drug development. She started in the cancer research labs at the University of Wisconsin and then moved into business development, medical affairs and clinical development roles within pharma and CRO. Her career has included thought leader engagement, product lifecycle planning, strategy development and execution for proposals and bid defenses, as well as corporate strategy and alliance management. Through her work with oncology investigators and patient advocacy organizations, she has been able to incorporate insights into patient-centric development strategies. Kientop is also a published author and cancer patient advocate.
Prior to joining Synteract, Kientop was the Vice President of Life Sciences at Inteliquet, a healthcare technology company. Previously, she held senior director strategy positions at two large CROs, as well as numerous biopharmaceutical organizations including MedImmune, MGI Pharma and Eisai.
Kientop holds a Bachelor of Science in Pharmacology and Toxicology and a Master of Business Administration from the University of Wisconsin.Message Presenter
Who Should Attend?
This webinar will appeal to VPs, Directors, Managers, Department Heads, Scientists and Researchers working within:
- Clinical R&D
- Clinical Research
- Clinical Pharmacology
- Clinical Operations
- Project Management
- Regulatory Affairs
- Medical Affairs
What You Will Learn
Key takeaways will include:
- The current landscape and direction of novel oncology therapies
- Evaluating and selecting the optimum trial design for targeted therapies such as immunotherapy, monoclonal antibodies and gene therapy
- Feasibility considerations, including advancements in resourcing and technology to help find and recruit patients and the increasing impact of COVID-19
- The significance that biomarkers and companion diagnostics play in the development of targeted therapies
With employees across 21 countries, Synteract is an innovative, full-service CRO supporting biopharma companies across all phases of drug development to help bring new medicines to market. Synteract has conducted 4,000 studies on six continents and in more than 60 countries, working with more than 26,000 investigative sites and 750,000 patients. Greater than 245 of its 4,000 studies have been in pediatric populations. In addition to pediatrics clinical trials, Synteract offers a notable depth of therapeutic expertise in dermatology, neurodegenerative, oncology and immunotherapy and rare/orphan disease studies.